ESSA Pharma Inc. (EPIX)
Stock Price:
$6.55 USD
0.06 (0.92%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
136.52M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-10.44M |
| Shares Out |
20.84M |
| EPS (ttm) |
-1.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$6.55 |
| Previous Close |
$6.49 |
| Change ($) |
0.06 |
| Change (%) |
0.92% |
| Day's Open |
6.50 |
| Day's Range |
6.36 - 6.73 |
| Day's Volume |
41,650 |
| 52-Week Range |
3.00 - 8.31 |
More Stats
| Market Cap |
136.52M |
| Enterprise Value |
86.64M |
| Earnings Date (est) |
Dec 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
20.84M |
| Float |
14.18M |
| EPS (basic) |
-1.24 |
| EPS (diluted) |
-1.03 |
| FCF / Share |
-1.45 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
12,645 |
| Short Ratio |
0.08 |
| Short % of Float |
0.09% |
| Beta |
1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.10 |
| Revenue |
n/a |
| Operating Income |
-12.17M |
| Net Income |
-10.44M |
| Free Cash Flow |
-12.25M |
| Net Cash |
49.89M |
| Net Cash / Share |
2.39 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-61.60% |
| ROE |
-106.04% |
| ROIC |
-729.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.00*
(83.21% upside)
Low
9.00
Current: $6.55
High
17.00
Target: 12.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -12.17 | -10.80 | -10.87 | -18.70 | -10.23 | -1.74 |
| Net Income | -10.44 | -11.63 | -4.50 | -13.14 | -9.68 | -1.82 |
| Shares Outstanding | 8.43 | 4.57 | 1.45 | 1.35 | 0.92 | 0.78 |
| Earnings Per Share | -1.24 | -2.55 | -3.09 | -9.77 | -10.60 | -2.40 |
| Operating Cash Flow | -12.25 | -10.22 | -17.35 | -15.30 | -13.34 | -2.08 |
| Capital Expenditures | - | - | - | -0.01 | -0.17 | - |
| Free Cash Flow | -12.25 | -10.22 | -17.35 | -15.31 | -13.51 | -2.08 |
| Cash & Equivalents | 53.60 | 15.03 | 3.96 | 8.99 | 1.58 | 3.70 |
| Total Debt | 3.71 | 6.32 | 7.96 | - | - | - |
| Net Cash / Debt | 49.89 | 8.71 | -4.00 | 8.99 | 1.58 | 3.70 |
| Assets | 54.77 | 16.02 | 5.61 | 10.40 | 7.54 | 4.20 |
| Liabilities | 5.59 | 6.87 | 9.88 | 10.94 | 3.08 | 2.23 |
| Book Value | 49.18 | 9.15 | -4.27 | -0.54 | 4.46 | 1.97 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ESSA Pharma Inc. |
| Country |
Canada |
| CEO |
David R. Parkinson |
Stock Information
| Ticker Symbol |
EPIX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: EPIX |
Description
ESSA Pharma engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.